The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | WGS of cfDNA for assessment of MRD in high-risk smoldering multiple myeloma
Chrissy Baker, MSc, PhD(c), University of Miami Miller School of Medicine, Miami, FL, discusses the potential of plasma-based cell-free DNA (cfDNA) analysis to assess measurable residual disease (MRD) in high-risk smoldering multiple myeloma (SMM). She explains how whole genome sequencing (WGS) of blood samples can capture disease heterogeneity, predict clinical outcomes, identify genomic drivers, and track disease progression, offering a less invasive alternative to bone marrow biopsies. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
